Use of antihistamine medications during early pregnancy and isolated major malformations

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 85, Issue 2, 2009, Pages 137-150

  Gilboa, Suzanne M ^a   Strickland, Matthew J ^a   Olshan, Andrew F ^b   Werler, Martha M ^c   Correa, Adolfo ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b IL   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

Antihistamine; Bayesian methods; Birth defects; H1 blockers; Pregnancy

Indexed keywords

ANTIHISTAMINIC AGENT; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CLEMASTINE; DIMENHYDRINATE; DIPHENHYDRAMINE; DOXYLAMINE; FEXOFENADINE; HYDROXYZINE; LORATADINE; MECLOZINE; PHENIRAMINE; PROMETHAZINE; TRIPROLIDINE;

ADULT; ANENCEPHALUS; ANOTIA; ANUS ATRESIA; AORTA COARCTATION; ARTICLE; BAYES THEOREM; BIRTH DEFECT; CLEFT LIP; CLEFT PALATE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; COVARIANCE; CRANIOFACIAL SYNOSTOSIS; DIAPHRAGM HERNIA; DISEASE ASSOCIATION; DRUG USE; FALLOT TETRALOGY; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; GASTROSCHISIS; GREAT VESSELS TRANSPOSITION; HEART ATRIUM SEPTUM DEFECT; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART RIGHT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; HYPOSPADIAS; INFANT; LIMB DEFECT; MAJOR CLINICAL STUDY; MICROTIA; NEURAL TUBE DEFECT; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PULMONARY VALVE STENOSIS; SPINA BIFIDA;

ABNORMALITIES, DRUG-INDUCED; CASE-CONTROL STUDIES; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; HYPERSENSITIVITY; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES;

EID: 62949195516     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20513     Document Type: Article

References (46)

1. Aselton P, Jick H, Chentow SK, et al. 1984. Pyloric stenosis and maternal Bendectin exposure. Am J Epidemiol 120:251-256.
2. Boneva R, Moore C, Botto LD, et al. 1999. Nausea during pregnancy and congenital heart defects: A population-based case-control study. Am J Epidemiol 149:717-725.
3. Botto LD, Lin AE, Riehle-Colarusso T, et al. 2007. Seeking causes: Classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Mol Teratol 79:714-727.
4. Brent R. 2003. Bendectin and Birth Defects: Hopefully, the Final Chapter. Birth Defects Res A Clin Mol Teratol 67:79-87.
5. Brent RL. 1995. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol 9:337-349.
6. Briggs G, Freeman R, Yaffe S. 2005. Drugs in Pregnancy and Lactation. Sixth Edition. Philadelphia: Lippincott, Williams & Wilkins.
7. Centers for Disease Control and Prevention. 2004. Evaluation of an association between loratadine and hypospadias - United States, 1997-2001. MMWR 53:219-221.
8. Chiavegatto S, Oliveira C, Bernard M. 1997. Prenatal exposure of rats to diphenhydramine: Effects on physical development, open field, and gonadal hormone levels in adults. Neurotoxicol Teratol 19:511-516.
9. Cordero JF, Oakley GP, Greenberg F, et al. 1981. Is Bendectin a teratogen? JAMA 245:2307-2310.
10. Diav-Citrin O, Shechtman S, Aharonovich A, et al. 2003. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 111:1239-1243.
11. Elbourne D, Mutch L, Dauncey M, et al. 1985. Debendox revisited. Br J Obstet Gynecol 92:780-785.
12. Eskenazi B, Bracken MB. 1982. Bendectin (Debendox) as a risk factor for pyloric stenosis. Am J Obstet Gynecol 144:919-924.
13. Ferencz C, Loffredo CA, Rubin JD, Loffredo CA. 1993. Prescription and nonprescription drugs. In: Ferencz C, Rubin JD, Loffredo CA, and Magee CA, eds. Epidemiology of Congenital Heart Disease: The Baltimore-Washington Infant Study, 1981-1989. Perspectives in Pediatric Cardiology, vol. 4. Mount Kisco: Futura Publishing Company.
14. Golding J, Vivian S, Baldwin J. 1983. Maternal antinauseants and clefts of lip and palate. Hum Toxicol 2:63-73.
15. Greenland S. 2007. Bayesian perspectives for epidemiological research. II. Regression analysis. Int J Epidemiol 36:195-202.
16. Heinonen OP, Slone D, Shapiro S. 1977. Birth defects and drugs in pregnancy. Littleton, Massachusetts: Publishing Sciences Group, Inc.
17. Honein MA, Rasmussen SA, Reefhuis J, et al. 2007. Maternal smoking and environmental tobacco smoke exposure and the risk of orofacial clefts. Epidemiology 18:226-233.
18. Källén B. 2002. Use of antihistamine drugs in early pregnancy and delivery outcome. J Maternal Fetal Neonat Med 11:146-152.
19. Källén B, Mottet I. 2003. Delivery outcome after the use of meclozine in early pregnancy. Eur J Epidemiol 18:665-669.
20. Källén B, Olausson PO. 2001. Monitoring of maternal drug use and infant congenital malformations. Does loratadine cause hypospadias? Int J Risk Safety Med 14:115-119.
21. Källén B, Olausson PO. 2006. No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy. Int J Med Sci 3:106-107.
22. Kelley K, Kelley T, Kaufman D, et al. 2003. The Slone Drug Dictionary: A research driven pharmacoepidemiology tool. Pharmacoepidemiol Drug Safety 12:S168-169.
23. Khoury M, Botto LD, Mastroiacovo P, et al. 1994. Monitoring for multiple congenital anomalies: An international perspective. Am J Epidemiol 16:335-349.
24. Khoury M, Botto LD, Waters GD, et al. 1993. Monitoring for new multiple congenital anomalies in the search for human teratogens. Am J Med Genet 46:460-466.
25. King C. 1963. Teratogenic effects of meclizine hydrochloride on the rat. Science 141:353-355.
26. Kleinbaum D, Klein M. 2002. Logistic Regression: A Self-Learning Text. 2nd ed. Springer-Verlag, New York.
27. Li Z, Ren A, Liu J, et al. 2007. Maternal flu or fever, medication use, and neural tube defects: a population-based case-control study in Northern China. Birth Defects Res A Clin Mol Teratol 79:295-300.
28. McKeigue PM, Lamm SH, Linn S, et al. 1994. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology 50:27-37.
29. Milkovich L, van den Berg B. 1976. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 125:244-248.
30. Mitchell AA, Rosenberg L, Shapiro S, et al. 1981. Birth defects related to Bendectin use in pregnancy. I. Oral clefts and cardiac defects. JAMA 245:2311-2314.
31. Mitchell AA, Schwingl PJ, Rosenberg L, et al. 1983. Birth defects in relation to Bendectin use in pregnancy. II. Pyloric stenosis. Am J Obstet Gynecol 147:737-742.
32. Moretti ME, Caprara D, Coutinho CJ, et al. 2003. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 111:479-483.
33. Pedersen L, Nørgaard M, Skriver MV, et al. 2006a. Prenatal exposure to loratadine in children with hypospadias: a nested case-control study within the Danish National Birth Cohort. Am J Therapeutics 13:320-324.
34. Pedersen L, Skriver MV, Nørgaard M, et al. 2006b. Maternal use of loratadine during pregnancy and risk of hypospadias in offspring. Int J Med Sci 3:21-25.
35. Rasmussen SA, Olney RS, Holmes LB, et al. 2003. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67:193-201.
36. Reefhuis J, Honein MA. 2004. Maternal age and non-chromosomal birth defects, Atlanta - 1968-2000: teenager or thirty-something, who is at risk? Birth Defects Res A Clin Mol Teratol 70:572-579.
37. Romitti PA, Sun L, Honein MA, et al. 2007. Maternal periconceptional alcohol consumption and risk of orofacial clefts. Am J Epidemiol 166:775-785.
38. Rothman KJ, Fyler DC, Goldblatt A, et al. 1979. Exogenous hormones and other exposures of children with congenital heart disease. Am J Epidemiol 109:433-439.
39. Rubin JD, Ferencz C, Loffredo C. 1993. Use of prescription and non-prescription drugs in pregnancy. The Baltimore-Washington Infant Study Group. J Clin Epidemiol 46:581-589.
40. Saxen I. 1974. Letter: Cleft palate and maternal diphenhydramine intake. Lancet March 9:407-408.
41. Seto A, Einarson T, Koren G. 1997. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol 14:119-124.
42. Shiono PH, Klebanoff MA. 1989. Bendectin and human congenital malformations. Teratology 40:151-155.
43. Sturman G, Freeman P, Meade HM, et al. 2002. Further evidence that histamine H1-antagonists cause joint weakness in rat foetuses. Inflamm Res 51 Suppl 1:S65-S66.
44. Werler MM, Mitchell AA, Hernandez-Diaz S, et al. 2005. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 193:771-777.
45. Yoon PW, Rasmussen SA, Lynberg MC, et al. 2001. The National Birth Defects Prevention Study. Public Health Reports 116:32-40.
46. Zierler S, Rothman KJ. 1985. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 313:347-352.